The project is a joint effort by the Asdent association, Vall d' Hebrón Institute of Research and Nostrum Biodiscovery. Its goal is to study the molecular basis of this ultra-rare disease, which might eventually lead to the discovery of a potential cure.
Our competitive advantage relies on our proprietary softwares that combine supercomputing, along with AI and all-atom simulation methods. Used in synergy with best-of-market software, we propose optimized solutions for industrial needs in molecular modeling.Learn more
Experts in Biomolecules
Applying our top-notch academic and industrial research & development expertise in molecular modeling, NBD provides tailored, flexible and confidential services for its pharma and biotech clients to overcome their early discovery bottlenecks.Learn more
Drug Discovery Projects
From oncology to CNS pathologies and rare diseases, we are leading drug design projects with academic partners based on new MoAs aiming to generate first-in-class candidates. The first resulting patent applications are currently being filed at the EPO.Learn more
Dedication and Ethics
Our scientific standards have gained the trust of several public institutions that funded the company from its start by transferring outstanding basic research technologies that have been implemented into industrial tools for top notch Drug Discovery projects.Learn more
AstraZeneca in collaboration with Heptares Therapeutic, has made significant progress with the new target called PAR2.
The ISQBP President’s meeting is held every two years acting as a gathering point point for the community working on molecular simulations of biomolecular systems.
NBD scientific team has successfully transferred outstanding basic research technologies that have been implemented into industrial tools with direct impact in top notch Drug Discovery projects.See details